<code id='9CDCE14606'></code><style id='9CDCE14606'></style>
    • <acronym id='9CDCE14606'></acronym>
      <center id='9CDCE14606'><center id='9CDCE14606'><tfoot id='9CDCE14606'></tfoot></center><abbr id='9CDCE14606'><dir id='9CDCE14606'><tfoot id='9CDCE14606'></tfoot><noframes id='9CDCE14606'>

    • <optgroup id='9CDCE14606'><strike id='9CDCE14606'><sup id='9CDCE14606'></sup></strike><code id='9CDCE14606'></code></optgroup>
        1. <b id='9CDCE14606'><label id='9CDCE14606'><select id='9CDCE14606'><dt id='9CDCE14606'><span id='9CDCE14606'></span></dt></select></label></b><u id='9CDCE14606'></u>
          <i id='9CDCE14606'><strike id='9CDCE14606'><tt id='9CDCE14606'><pre id='9CDCE14606'></pre></tt></strike></i>

          Home / Wikipedia / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:76
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In